Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer

Molecular Pharmaceutics

Volumn 12, Issue 8, 2015, Pages 2781-2790

  Gourni, Eleni ^a,b   Del Pozzo, Luigi ^b   Kheirallah, Emilie ^b   Smerling, Christiane ^c   Waser, Beatrice ^d   Reubi, Jean Claude ^d   Paterson, Brett M ^e   Donnelly, Paul S ^e   Meyer, Philipp T ^b   Maecke, Helmut R ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Pharmaceuticals GmbH 3B   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

64Cu; gastrin releasing peptide receptor antagonists; PET imaging; sarcophagine MeCOSar chelator

Indexed keywords

5 (8 METHYL 3,6,10,13,16,19 HEXAAZA BICYCLO[6.6.6]ICOSAN 1 YLAMINO) 5 OXOPENTANOIC ACID; BICYCLO COMPOUND; BOMBESIN ANTAGONIST; CALCIUM; COPPER 64; GASTRIN RELEASING PEPTIDE RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; STATINE DERIVATIVE; UNCLASSIFIED DRUG; ALANYLTYROSINE; BOMBESIN RECEPTOR; COPPER; DIPEPTIDE; HETEROCYCLIC COMPOUND; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; HUMAN; HUMAN CELL; IC50; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTUM YIELD; RADIOACTIVITY; RECEPTOR AFFINITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; COPPER RADIOISOTOPES; DIPEPTIDES; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; MICE, NUDE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938603067     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500671j     Document Type: Article

References (42)

1. Schroeder, R. P. J.; van Weeden, W. M.; Bangma, C.; Krenning, E. P.; de Jong, M. Peptide receptor imaging of prostate cancer with radiolabeled bombesin analogues Methods 2009, 48, 200-204 10.1016/j.ymeth.2009.04.002
2. Mansi, R.; Fleischmann, A.; Maecke, H. R.; Reubi, J. C. Targeting GRPR in urological cancers-from basic research to clinical application Nat. Rev. Urol. 2013, 10, 235-244 10.1038/nrurol.2013.42
3. Sancho, V.; Di Florio, A.; Moody, T.; Jensen, R. T. Bombesin receptor mediated imaging and cytotoxicity: review and current status Curr. Drug Delivery 2011, 8, 79-134 10.2174/156720111793663624
4. Van de Wiele, C.; Phonteyne, P.; Pauwels, P.; Goethals, I.; Van den Broecke, R.; Cocquyt, V.; Dierckx, R. A. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry J. Nucl. Med. 2008, 49, 260-264 10.2967/jnumed.107.047167
5. Van de Wiele, C.; Dumont, F.; Vanden Broecke, R.; Oosterlinck, W.; Cocquyt, V.; Serreyn, R.; Peers, S.; Thornback, J.; Slegers, G.; Dierckx, R. A. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study Eur. J. Nucl. Med. Mol. Imaging 2000, 27, 1694-1699 10.1007/s002590000355
6. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations Eur. J. Nucl. Med. Mol. Imaging 2007, 34, S221
7. Casanueva, F. F.; Perez, F. R.; Casabiell, X.; Camina, J. P.; Cai, R. Z.; Schally, A. V. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 1406-1411 10.1073/pnas.93.4.1406
8. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Mäcke, H. R.; Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 16436-16441 10.1073/pnas.0607761103
9. Anderson, C. J.; Ferdani, R. Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research Cancer Biother.Radiopharm. 2009, 24, 379-393 10.1089/cbr.2009.0674
10. 64Cu-bombesin analogs: Side-by-side comparison of CB-TE2A and DOTA chelation systems J. Nucl. Med. 2007, 48, 1327-1337 10.2967/jnumed.107.039487
11. Liu, Y.; Hu, X.; Liu, H.; Bu, L.; Ma, X.; Cheng, K.; Li, J.; Tian, M.; Zhang, H.; Cheng, Z. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer J. Nucl. Med. 2013, 54, 2132-2138 10.2967/jnumed.113.121533
12. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma Nucl. Med. Biol. 2006, 33, 371-380 10.1016/j.nucmedbio.2005.12.011
13. 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer Nucl. Med. Biol. 2012, 39, 609-616 10.1016/j.nucmedbio.2011.12.004
14. 3]bombesin in human prostate adenocarcinoma xenografts J. Nucl. Med. 2004, 45, 1390-1397
15. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer J. Nucl. Med. 2011, 52, 470-477 10.2967/jnumed.110.082826
16. 2] targeting vector for positron-emission tomography imaging of gastrin-realising peptide receptor-expressing tissues Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 12462-12467 10.1073/pnas.0705347104
17. Abiraj, K.; Mansi, R.; Tamma, M. L.; Fani, M.; Forrer, F.; Nicolas, G.; Cescato, R.; Reubi, J. C.; Mäcke, H. R. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors J. Nucl. Med. 2011, 52, 1970-1978 10.2967/jnumed.111.094375
18. 14]BBN(6-14) Bioconjugate Chem. 2012, 23, 1687-1693 10.1021/bc3002437
19. Mansi, R.; Wang, X.; Forrer, F.; Kneifel, S.; Tamma, M. L.; Waser, B.; Cescato, R.; Reubi, J. C.; Mäcke, H. R. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides Clin. Cancer Res. 2009, 15, 5240-5249 10.1158/1078-0432.CCR-08-3145
20. Mansi, R.; Wang, X.; Forrer, F.; Waser, B.; Cescato, R.; Graham, K.; Borkowski, S.; Reubi, J. C.; Mäcke, H. R. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRP-r-positive tumors Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 97-107 10.1007/s00259-010-1596-9
21. Jamous, M.; Tamma, M. L.; Gourni, E.; Waser, B.; Reubi, J. C.; Mäcke, H. R.; Mansi, R. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists Nucl. Med. Biol. 2014, 41, 464-470 10.1016/j.nucmedbio.2014.03.014
22. Wieser, G.; Mansi, R.; Grosu, A. L.; Schultze-Seemann, W.; Dumont-Walter, R. A.; Meyer, P. T.; Maecke, H. R.; Reubi, J. C.; Weber, W. A. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist-from mice to men Theranostics 2014, 4, 412-419 10.7150/thno.7324
23. 64Cu-labeled peptides for PET imaging J. Nucl. Med. 2014, 55, 1719-1725 10.2967/jnumed.114.141242
24. Smith, S. V. Sarar technology for the application of copper-64 in biology and materials science Q. J. Nucl. Mol. Imaging 2008, 52, 193-202
25. 64Cu radiopharmaceutcals Nucl. Med. Biol. 2010, 37, 57-65 10.1016/j.nucmedbio.2009.09.001
26. 64Cu radiolabeling J. Chem. Soc., Dalton Trans. 2009, 27, 5395-5400 10.1039/b902210d
27. Ma, M. T.; Karas, J. A.; White, J. M.; Scanlon, D.; Donnelly, P. S. A new bifunctional chelator for copper radiopharmaceuticals: a cage amine ligand with a carboxylate functional group for conjugation to peptides Chem. Commun. 2009, 3237-3239 10.1039/b903426a
28. Di Bartolo, N. M.; Sargeson, A. M.; Donlevy, T. M.; Smith, S. V. Synthesis of a new cage ligand, SarAr, and its coplexation with selected transition metal ions for potential use in radioimaging J. Chem. Soc., Dalton Trans. 2001, 15, 2303-2309 10.1039/b103242a
29. 64Cu-SarAr immunoconjugates Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 17489-17493 10.1073/pnas.0708436104
30. 3-octreotate Dalton Trans. 2014, 43, 1386-1396 10.1039/C3DT52647J
31. Hricak, H.; Choyke, P. L.; Eberhardt, S. C.; Leibel, S. A.; Scardino, P. T. Imaging prostate cancer: A multidisciplinary perspective Radiology 2007, 243, 28-53 10.1148/radiol.2431030580
32. Markwalder, R.; Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Res. 1999, 59, 1152-1159
33. Beer, A. J.; Eiber, M.; Souvatzoglou, M.; Schwaiger, M.; Krause, B. J. Radionuclide and hybrid imaging of recurrent prostate cancer Lancet Oncol. 2011, 12, 181-191 10.1016/S1470-2045(10)70103-0
34. Llinares, M.; Devin, C.; Chaloin, O.; Azay, J.; Noel-Artis, A. M.; Bernad, N.; Fehrentz, J. A.; Martinez, J. Synthesis and biological activities of potent bombesin receptor antagonists J. Pept. Res. 1999, 53, 275-283 10.1034/j.1399-3011.1999.00028.x
35. Blower, P. J.; Lewis, J. S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine Nucl. Med. Biol. 1996, 23, 957-980 10.1016/S0969-8051(96)00130-8
36. Turski, M. L.; Thiele, D. J. New roles for copper metabolism in cell proliferation, signaling, and disease J. Biol. Chem. 2009, 284, 717-721 10.1074/jbc.R800055200
37. 64Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability Bioconjugate Chem. 2012, 23, 1029-1039 10.1021/bc300037w
38. 3-bombesin targeting peptides Inorg. Chem. 2011, 50, 6701-6710 10.1021/ic200681s
39. Abd-Elgaliel, W. R.; Gallazzi, F.; Garrison, J. C.; Rold, T. L.; Sieckman, G. L.; Figueroa, S. D.; Hoffman, T. J.; Lever, S. Z. Design, synthesis and biological evaluation of an antagonist-bombesin analogue as targeting vector Bioconjugate Chem. 2008, 19, 2040-2048 10.1021/bc800290c
40. 111In-labeling, and preclinical profile J. Med. Chem. 2013, 56, 2374-2384 10.1021/jm301692p
41. 3 expression Bioconjugate Chem. 2010, 21, 1417-1424 10.1021/bc900537f
42. 64Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity Nucl. Med. Biol. 2009, 36, 277-285 10.1016/j.nucmedbio.2008.12.008